Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01829737 · ClinicalTrials.gov registry record

Malaria Transmission Studies in Mali

A clinical trial of Malaria, Falciparum, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
534
Enrollment target
1
Study location

NCT01829737: Completed study of Malaria, Falciparum, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT01829737 is a study of Malaria, Falciparum that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 534 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01829737, a study of Malaria, Falciparum, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
534 participants
Enrollment target
1
Study location

Study Summary

Background: \- Malaria is an illness caused by a parasite spread by mosquitoes. When a mosquito bites a person who is infected with a kind of parasite called a gametocyte, it is able to spread the infection to another person. Not everyone infected with parasites have gametocytes in their blood. As a result, not everyone can spread malaria to others. Researchers are interested in learning more about why some healthy people have gametocytes in their blood and others do not. Identifying the people who have gametocytes in their blood can help target treatment and reduce the spread of malaria. This study will focus on the people of the village of Kenieroba in Mali, where malaria is common. Objectives: \- To study the relationship between gametocytes and malaria transmission in Mali. Eligibility: \- Individuals between 6 months and 65 years of age who live in Kenieroba, Mali, and will stay in the area for 1 year. Design: * For 1 year, participants will have study visits once every 2 weeks (twice a month, for a total of 24 visits). The visits will last 30 minutes each. * At each visit, participants will provide a small blood sample. They will report any symptoms of malaria such as fever, headache, and body aches. Participants will be encouraged to seek medical treatment if they experience malaria symptoms between visits. * Participants who have malaria symptoms will have a blood test for malaria parasites. Those who have parasites in the blood will receive antimalarial treatment. * Three times over 1 year, a larger blood sample will be collected. These blood samples will be taken once in the dry season, once in the wet season, and once in the next dry season. * Women between 14 and 45 years of age will also provide urine samples to test for pregnancy. Pregnant women will not be asked to give blood samples.

Conditions Studied

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda

Trial Details

FieldValue
Enrollment Target 534 participants
Start Date 2013-03-20
Est. Completion 2015-01-20

What the finished NCT01829737 record still lists

NCT01829737 is an observational study that tracks outcomes without assigning an intervention. The registered 534 participants enrollment target is mid-sized for trials with a published cap.

The record links to 1 condition, with Malaria, Falciparum appearing as the primary indexed condition, and to 0 interventions.

NCT01829737 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT01829737 about?

NCT01829737 is a clinical study titled "Malaria Transmission Studies in Mali". Background: \- Malaria is an illness caused by a parasite spread by mosquitoes. When a mosquito bites a person who is infected with a kind of parasite called a gametocyte, it is able to spread the infection to another person. Not everyone infected with parasites have gametocytes in their blood. As ...

What is the current status of trial NCT01829737?

This trial is currently completed. The enrollment target is 534 participants. The study started on 2013-03-20. Estimated completion is 2015-01-20.

What conditions does trial NCT01829737 study?

This clinical trial studies the following conditions: Malaria, Falciparum.

Who is sponsoring clinical trial NCT01829737?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01829737 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04910685 · 534 participants · Phase 2

    (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

  • NCT06128551 · 534 participants · Phase 1

    Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  • NCT05614739 · 535 participants · Phase 1

    FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

  • NCT07091617 · 535 participants · NA

    Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01829737, the US trial registry maintained by the National Library of Medicine. NCT01829737 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.